Loading clinical trials...
Loading clinical trials...
Comparison between two diagnostic modalities for breast cancer diagnosis. Two different imaging systems are compared to evaluate the performance of the two systems
The diagnostic quality of MRI of the breast has made this method a gold standard in the imaging of senologic lesions. Low-dose dedicated breast CT (BCT) with single photon-detection (nu:view, developed by AB-CT - Advanced Breast-CT GmbH) has emerged as a fully 3D imaging modality that uses ionizing radiation comparable to 2D mammography and has its intended use in helping with diagnosis in diagnostic breast imaging. The investigation is designed as a prospective non-randomized intra-individual cohort procedure comparison between the imaging platforms, nu:view and MRI. Across 3 hospital-based study sites in two countries, study participants (patients who meet study criteria and have consented) sequentially receive nu:view imaging and, with a delay of up to one week (preferably on the same day), MRI imaging. At both times, patients receive contrast agent. Images generated from breasts are evaluated by three independent radiologists and their scores and interpretations are statistically evaluated. The research aim is to demonstrate non-inferiority of BCT compared with MRI in major indications of MRI for breast diagnostics. The perceived gain in the study is to generate data on clinical performance of the BCT device nu:view and on the procedure that could be supportive of a tailored use of nu:view in patients with major indications of MRI for breast diagnostics.
Age
18 - No limit years
Sex
FEMALE
Healthy Volunteers
Yes
DRZ Die Radiologen
Regensburg, Bavaria, Germany
Radiologisches Institut Universitätsklinikum Erlangen
Erlangen, Germany
Stichting Martini Ziekenhuis
Groningen, Netherlands
Leiden University Medical Centre
Leiden, Netherlands
Start Date
November 24, 2023
Primary Completion Date
December 1, 2025
Completion Date
December 1, 2025
Last Updated
January 30, 2025
428
ESTIMATED participants
Injection of contrast enhancing agent Gadovist for MRI investigation
DIAGNOSTIC_TEST
Injection of contrast enhancing agent Imeron for B-CT investigation
DIAGNOSTIC_TEST
Lead Sponsor
AB-CT - Advanced Breast-CT GmbH
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions